Summary: Glucose-lowering SGLT2 inhibitors, the inflammation-lowering drug Canakinumab, cholesterol-lowering PCSK9 inhibitors, and using gene editing to fix mutations, were named by the AHA in its list of the top advances in heart disease and stroke research of 2017. [This article first appeared on the website LongevityFacts. Author: Brady Hartman.] Here’s an executive summary of four of these top research advances: Fixing Genetic Mutation in Human Embryos When… Continue reading "AHA names 2017’s top advances in heart disease and stroke research"
Summary: SGLT2 inhibitors, a widely heralded class of diabetes drugs, were shown to significantly lower the rates of heart failure and death in the CVD-REAL study. [This article first appeared on LongevityFacts. Author: Brady Hartman. ] The new SGLT2 inhibitors are a class of diabetes treatments shown in observational studies to have lower rates of heart failure and death when compared to other glucose-lowering… Continue reading "Diabetes treating ‘SGLT2 inhibitors’ named among top advances for preventing heart disease"
Summary: The AHA names the PCSK9 inhibitor evolocumab as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8. However, this novel cholesterol-lowering drug carries a big price tag. [This article first appeared on LongevityFacts. Author: Brady Hartman. ] The AHA named the cholesterol-lowering drug evolocumab in its annual top 10 lists of major advances… Continue reading "AHA names PCSK9 inhibitor evolocumab as a top advance in heart disease"